{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:55:40Z","timestamp":1793318140824,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Volumetric magnetic resonance imaging (vMRI) has been widely studied in Huntington's disease (HD) and is commonly used to assess treatment effects on brain atrophy in interventional trials. Global and regional trajectories of brain atrophy in HD, with early involvement of striatal regions, are becoming increasingly understood. However, there remains heterogeneity in the methods used and a lack of widely-accessible multisite, longitudinal, normative datasets in HD. Consensus for standardized practices for data acquisition, analysis, sharing, and reporting will strengthen the interpretation of vMRI results and facilitate their adoption as part of a pathobiological disease staging system. The Huntington's Disease Regulatory Science Consortium (HD-RSC) currently comprises 37 member organizations and is dedicated to building a regulatory science strategy to expedite the approval of HD therapeutics. Here, we propose four recommendations to address vMRI standardization in HD research: (1) a checklist of standardized practices for the use of vMRI in clinical research and for reporting results; (2) targeted research projects to evaluate advanced vMRI methodologies in HD; (3) the definition of standard MRI-based anatomical boundaries for key brain structures in HD, plus the creation of a standard reference dataset to benchmark vMRI data analysis methods; and (4) broad access to raw images and derived data from both observational studies and interventional trials, coded to protect participant identity. In concert, these recommendations will enable a better understanding of disease progression and increase confidence in the use of vMRI for drug development.<\/jats:p>","DOI":"10.3389\/fneur.2021.712565","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T05:30:09Z","timestamp":1634880609000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Kirsi M.","family":"Kinnunen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana P.","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian","family":"Pustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael I.","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Gantman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nellie","family":"Georgiou-Karistianis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell."},{"key":"B2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B3","unstructured":"Huntington's disease integrated staging system (HD-ISS): a novel evidence-based classification system for staging\n            TabriziSJ\n            SchobelS\n            GantmanEC\n            MansbachA\n            BorowskyB\n            KonstantinovaP\n          medRxiv [Preprint].2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","article-title":"Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis","volume":"19","author":"Scahill","year":"2020","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/B978-0-12-801893-4.00020-1","article-title":"Structural imaging in premanifest and manifest Huntington disease","volume":"144","author":"Scahill","year":"2017","journal-title":"Handb Clin Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3389\/fneur.2021.712555","article-title":"Volumetric MRI-based biomarkers in Huntington's disease: an evidentiary review","volume":"12","author":"Kinnunen","year":"2021","journal-title":"Front Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Huntington Study Group","volume":"11","year":"1996","journal-title":"Mov Disord."},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1201\/9780429492259","volume-title":"Flexible Imputation of Missing Data","author":"van Buuren","year":"2018"},{"key":"B10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/WCO.0b013e32832d92de","article-title":"Multisite neuroimaging trials","volume":"22","author":"Van Horn","year":"2009","journal-title":"Curr Opin Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s13311-021-01027-4","article-title":"The use, standardization, and interpretation of brain imaging data in clinical trials of neurodegenerative disorders","volume":"18","author":"Schwarz","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neurobiolaging.2015.09.018","article-title":"MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials","volume":"37","author":"Hua","year":"2016","journal-title":"Neurobiol Aging."},{"key":"B13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12021-017-9326-0","article-title":"Alzheimer's disease neuroimaging initiative. A comparison of accelerated and non-accelerated MRI scans for brain volume and boundary shift integral measures of volume change: evidence from the ADNI dataset","volume":"15","author":"Manning","year":"2017","journal-title":"Neuroinformatics."},{"key":"B14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neuroimage.2014.11.049","article-title":"Alzheimer's disease neuroimaging initiative. Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement","volume":"107","author":"Leung","year":"2015","journal-title":"Neuroimage."},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuroimage.2015.11.054","article-title":"Prospective motion correction with volumetric navigators (vNavs) reduces the bias and variance in brain morphometry induced by subject motion","volume":"127","author":"Tisdall","year":"2016","journal-title":"Neuroimage."},{"key":"B16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jalz.2014.05.1756","article-title":"The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity","volume":"11","author":"Frisoni","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jalz.2015.01.002","article-title":"Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project","volume":"11","author":"Duchesne","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jalz.2014.02.009","article-title":"Delphi definition of the EADC-ADNI harmonized protocol for hippocampal segmentation on magnetic resonance","volume":"11","author":"Boccardi","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jalz.2011.04.007","article-title":"Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/0962280214537344","article-title":"Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment","volume":"24","author":"Raunig","year":"2015","journal-title":"Stat Methods Med Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s43441-020-00255-8","article-title":"Effective data sharing as a conduit for advancing medical product development","volume":"55","author":"Karpen","year":"2021","journal-title":"Ther Innov Regul Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jalz.2015.04.005","article-title":"Impact of the Alzheimer's disease neuroimaging initiative, 2004 to 2014","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving Alzheimer's disease clinical trials: recent highlights from the Alzheimer's Disease neuroimaging initiative","volume":"15","author":"Veitch","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jalz.2015.04.001","article-title":"Perspective: the Alzheimer's disease neuroimaging initiative and the role and contributions of the private partner scientific board (PPSB)","volume":"11","author":"Liu","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1056\/NEJMc1908881","article-title":"Identification of anonymous MRI research participants with face-recognition software","volume":"381","author":"Schwarz","year":"2019","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/cts.12845","article-title":"Standardized data structures in rare diseases: CDISC user guides for duchenne muscular Dystrophy and Huntington's Disease","volume":"14","author":"Mullin","year":"2020","journal-title":"Clin Transl Sci."},{"key":"B27","unstructured":"Huntington's Disease Therapeutic Area User Guide v1.0"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.712565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T05:30:13Z","timestamp":1634880613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.712565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":27,"alternative-id":["10.3389\/fneur.2021.712565"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.712565","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"article-number":"712565"}}